Neuropeptides
Volume 44, Issue 1 , Pages 45-51 , February 2010

PACAP and VIP affect NF1 expression in rat malignant peripheral nerve sheath tumor (MPNST) cells

  • Salvatore Giunta

      Affiliations

    • Department of Anatomy, Diagnostic Pathology, Legal Medicine, Hygiene and Public Health, University of Catania, Catania, Italy
    • Neuropharmacology PhD Program, University of Catania, Catania, Italy
    • ,
  • Alessandro Castorina

      Affiliations

    • Department of Anatomy, Diagnostic Pathology, Legal Medicine, Hygiene and Public Health, University of Catania, Catania, Italy
    • ,
  • Alexander Adorno

      Affiliations

    • Department of Anatomy, Diagnostic Pathology, Legal Medicine, Hygiene and Public Health, University of Catania, Catania, Italy
    • ,
  • Venera Mazzone

      Affiliations

    • Department of Anatomy, Diagnostic Pathology, Legal Medicine, Hygiene and Public Health, University of Catania, Catania, Italy
    • ,
  • Maria Luisa Carnazza

      Affiliations

    • Department of Anatomy, Diagnostic Pathology, Legal Medicine, Hygiene and Public Health, University of Catania, Catania, Italy
    • ,
  • Velia D’Agata

      Affiliations

    • Department of Anatomy, Diagnostic Pathology, Legal Medicine, Hygiene and Public Health, University of Catania, Catania, Italy
    • Corresponding Author InformationCorresponding author. Address: Department of Anatomy, Diagnostic Pathology, Legal Medicine, Hygiene and Public Health, Via S. Sofia, 87, 95123 Catania, Italy. Tel.: +39 095 3782147; fax: +39 095 3782046.

Received 17 July 2009 ,Accepted 15 October 2009.

References 

  1. Arimura A. Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems. Jpn. J. Physiol. 1998;48:301–331
  2. Aubert N, Falluel-Morel A, Vaudry D, Xifro X, Rodriguez-Alvarez J, Fisch C, et al. PACAP and C2-ceramide generate different AP-1 complexes through a MAP-kinase-dependent pathway: involvement of c-Fos in PACAP-induced Bcl-2 expression. J. Neurochem. 2006;99:1237–1250
  3. Bhave SV, Hoffman PL. Phosphatidylinositol 3′-OH kinase and protein kinase A pathways mediate the anti-apoptotic effect of pituitary adenylyl cyclase-activating polypeptide in cultured cerebellar granule neurons: modulation by ethanol. J. Neurochem. 2004;88:359–369
  4. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976;72:248–254
  5. Brenneman DE. Neuroprotection: a comparative view of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Peptides. 2007;28:1720–1726
  6. Carroll SL, Ratner N. How does the Schwann cell lineage form tumors in NF1?. Glia. 2008;56:1590–1605
  7. Castorina A, Tiralongo A, Giunta S, Carnazza ML, Rasi G, D’Agata V. PACAP and VIP prevent apoptosis in schwannoma cells. Brain Res. 2008;1241:29–35
  8. Cavallaro S, Copani A, D’Agata V, Musco S, Petralia S, Ventra C, et al. Pituitary adenylate cyclase activating polypeptide prevents apoptosis in cultured cerebellar granule neurons. Mol. Pharmacol. 1996;50:60–66
  9. Dasgupta B, Gutmann DH. Neurofibromin regulates neural stem cell proliferation, survival, and astroglial differentiation in vitro and in vivo. J. Neurosci. 2005;25:5584–5594
  10. DeClue JE, Stone JC, Blanchard RA, Papageorge AG, Martin P, Zhang K, et al. A Ras effector domain mutant which is temperature sensitive for cellular transformation: interactions with GTPase-activating protein and NF-1. Mol. Cell. Biol. 1991;11:3132–3138
  11. Dejda A, Jolivel V, Bourgault S, Seaborn T, Fournier A, Vaudry H, et al. Inhibitory effect of PACAP on caspase activity in neuronal apoptosis: a better understanding towards therapeutic applications in neurodegenerative diseases. J. Mol. Neurosci. 2008;36:26–37
  12. Delcourt N, Thouvenot E, Chanrion B, Galéotti N, Jouin P, Bockaert J, et al. PACAP type I receptor transactivation is essential for IGF-1 receptor signalling and antiapoptotic activity in neurons. EMBO J. 2007;26:1542–1551
  13. Dickinson T, Fleetwood-Walker SM. VIP and PACAP: very important in pain?. Trends Pharmacol. Sci. 1999;20:324–329
  14. Dickson L, Finlayson K. VPAC and PAC receptors: from ligands to function. Pharmacol. Ther. 2009;121:294–316
  15. Dvoráková MC. Cardioprotective role of the VIP signaling system. Drug News Perspect. 2005;18:387–391
  16. Falluel-Morel A, Aubert N, Vaudry D, Basille M, Fontaine M, Fournier A, et al. Opposite regulation of the mitochondrial apoptotic pathway by C2-ceramide and PACAP through a MAP-kinase-dependent mechanism in cerebellar granule cells. J. Neurochem. 2004;91:1231–1243
  17. Gasz B, Rácz B, Roth E, Borsiczky B, Ferencz A, Tamás A, et al. Pituitary adenylate cyclase activating polypeptide protects cardiomyocytes against oxidative stress-induced apoptosis. Peptides. 2006;27:87–94
  18. Gomariz RP, Martinez C, Abad C, Leceta J, Delgado M. Immunology of VIP: a review and therapeutical perspectives. Curr. Pharm. Des. 2001;7:89–111
  19. Gonzalez-Rey E, Chorny A, Delgado M. Regulation of immune tolerance by anti-inflammatory neuropeptides. Nat. Rev. Immunol. 2007;7:52–63
  20. Harmar AJ, Marston HM, Shen S, Spratt C, West KM, Sheward WJ, et al. The VPAC(2) receptor is essential for circadian function in the mouse suprachiasmatic nuclei. Cell. 2002;109:497–508
  21. Hiatt KK, Ingram DA, Zhang Y, Bollag G, Clapp DW. Neurofibromin GTPase-activating protein-related domains restore normal growth in Nf1−/− cells. J. Biol. Chem. 2007;276:7240–7245
  22. Isobe K, Tatsuno I, Yashiro T, Nanmoku T, Takekoshi K, Kawakami Y, et al. Expression of mRNA for PACAP and its receptors in intra- and extra-adrenal human pheochromocytomas and their relationship to catecholamine synthesis. Regul. Pept. 2003;110:213–217
  23. Iyer VR, Eisen MB, Ross DT, Schuler G, Moore T, Lee JC, et al. The transcriptional program in the response of human fibroblasts to serum. Science. 1999;283:83–87
  24. Jamen F, Bouschet T, Laden JC, Bockaert J, Brabet P. Up-regulation of the PACAP type-1 receptor (PAC1) promoter by neurotrophins in rat PC12 cells and mouse cerebellar granule cells via the Ras/mitogen-activated protein kinase cascade. J. Neurochem. 2002;82:1199–1207
  25. Jaworski DM. Expression of pituitary adenylate cyclase-activating polypeptide (PACAP) and the PACAP-selective receptor in cultured rat astrocytes, human brain tumors, and in response to acute intracranial injury. Cell Tissue Res. 2000;300:219–230
  26. Johnson MR, DeClue JE, Felzmann S, Vass WC, Xu G, White R, et al. Neurofibromin can inhibit Ras-dependent growth by a mechanism independent of its GTPase-accelerating function. Mol. Cell. Biol. 1994;14:641–645
  27. Lelievre V, Ghiani CA, Seksenyan A, Gressens P, de Vellis J, Waschek JA. Growth factor-dependent actions of PACAP on oligodendrocyte progenitor proliferation. Regul. Pept. 2006;137:58–66
  28. Li Y, Gonzalez MI, Meinkoth JL, Field J, Kazanietz MG, Tennekoon GI. Lysophosphatidic acid promotes survival and differentiation of rat Schwann cells. J. Biol. Chem. 2003;278:9585–9591
  29. Lindholm D, Skoglösa Y, Takei N. Developmental regulation of pituitary adenylate cyclase activating polypeptide (PACAP) and its receptor 1 in rat brain: function of PACAP as a neurotrophic factor. Ann. NY Acad. Sci. 1998;865:189–196
  30. Liu, X., Hou, J., Shi, L., Chen, J., Chen, X., Sang, J., Hu, S., Cong, X., 2009. Lysophosphatidic acid protects mesenchymal stem cells against ischemia induced apoptosis in vivo. Stem Cells Dev. [Epub ahead of print].
  31. Mews M, Meyer M. Modulation of Schwann cell phenotype by TGF-beta 1: inhibition of P0 mRNA expression and downregulation of the low affinity NGF receptor. Glia. 1993;8:208–217
  32. Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, Jiang L, et al. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem. Biophys. Res. Commun. 1989;164:567–574
  33. Miyata A, Jiang L, Dahl RD, Kitada C, Kubo K, Fujino M, et al. Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem. Biophys. Res. Commun. 1990;170:643–648
  34. Ohtaki H, Nakamachi T, Dohi K, Aizawa Y, Takaki A, Hodoyama K, et al. Pituitary adenylate cyclase-activating polypeptide (PACAP) decreases ischemic neuronal cell death in association with IL-6. Proc. Natl. Acad. Sci. USA. 2006;103:7488–7493
  35. Parada LF. Neurofibromatosis type 1. Biochim. Biophys. Acta. 2000;1471:M13–M19
  36. Pascale A, Fortino I, Covoni S, Trabucchi M, Wetsel WC, Battaini F. Functional impairment in protein kinase C by RACK1 (receptor for activated C kinase 1) deficiency in aged rat brain cortex. J. Neurochem. 1996;67:2471–2477
  37. Pébay A, Torrens Y, Toutant M, Cordier J, Glowinski J, Tencé M. Pleiotropic effects of lysophosphatidic acid on striatal astrocytes. Glia. 1999;28:25–33
  38. Pozo D, Delgado M. The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide?. FASEB J. 2004;18:1325–1334
  39. Przywara DA, Kulkarni JS, Wakade TD, Leontiev DV, Wakade AR. Pituitary adenylyl cyclase-activating polypeptide and nerve growth factor use the proteasome to rescue nerve growth factor-deprived sympathetic neurons cultured from chick embryos. J. Neurochem. 1998;71:1889–1897
  40. Rácz B, Gasz B, Borsiczky B, Gallyas F, Tamás A, Józsa R, et al. Protective effects of pituitary adenylate cyclase activating polypeptide in endothelial cells against oxidative stress-induced apoptosis. Gen. Comp. Endocrinol. 2007;153:115–123
  41. Reubi JC. In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications. Ann. NY Acad. Sci. 2000;921:1–25
  42. Scharf E, May V, Braas KM, Shutz KC, Mao-Draayer Y. Pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) regulate murine neural progenitor cell survival, proliferation, and differentiation. J. Mol. Neurosci. 2008;36:79–88
  43. Shapira S, Barkan B, Friedman E, Kloog Y, Stein R. The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways. Cell Death Differ. 2007;14:895–906
  44. Somogyvári-Vigh A, Reglodi D. Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide. Curr. Pharm. Des. 2004;10:2861–2889
  45. Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell. 2009;136:731–745
  46. Thomas SL, Deadwyler GD, Tang J, Stubbs EB, Muir D, Hiatt KK, et al. Reconstitution of the NF1 GAP-related domain in NF1-deficient human Schwann cells. Biochem. Biophys. Res. Commun. 2006;348:971–980
  47. Trachtenberg JT, Thompson WJ. Schwann cell apoptosis at developing neuromuscular junctions is regulated by glial growth factor. Nature. 1996;379:174–177
  48. Tucker T, Friedman JM. Pathogenesis of hereditary tumors: beyond the “two-hit” hypothesis. Clin. Genet. 2002;62:345–357
  49. Uchida D, Arimura A, Somogyvári-Vigh A, Shioda S, Banks WA. Prevention of ischemia-induced death of hippocampal neurons by pituitary adenylate cyclase activating polypeptide. Brain Res. 1996;736:280–286
  50. Ushiyama M, Ikeda R, Sugawara H, Yoshida M, Mori K, Kangawa K, et al. Differential intracellular signaling through PAC1 isoforms as a result of alternative splicing in the first extracellular domain and the third intracellular loop. Mol. Pharmacol. 2007;72:103–111
  51. Vaudry D, Basille M, Anouar Y, Fournier A, Vaudry H, Gonzalez BJ. The neurotrophic activity of PACAP on rat cerebellar granule cells is associated with activation of the protein kinase A pathway and c-fos gene expression. Ann. NY Acad. Sci. 1998;865:92–99
  52. Vaudry D, Pamantung TF, Basille M, Rousselle C, Fournier A, Vaudry H, et al. PACAP protects cerebellar granule neurons against oxidative stress-induced apoptosis. Eur. J. Neurosci. 2002;15:1451–1460
  53. Vaudry D, Rousselle C, Basille M, Falluel-Morel A, Pamantung TF, Fontaine M, et al. Pituitary adenylate cyclase-activating polypeptide protects rat cerebellar granule neurons against ethanol-induced apoptotic cell death. Proc. Natl. Acad. Sci. USA. 2002;99:6398–6403
  54. Waschek JA. VIP and PACAP receptor-mediated actions on cell proliferation and survival. Ann. NY Acad. Sci. 1996;805:290–300
  55. Waschek JA, Casillas RA, Nguyen TB, DiCicco-Bloom EM, Carpenter EM, Rodriguez WI. Neural tube expression of pituitary adenylate cyclase activating peptide (PACAP) and receptor: potential role in patterning and neurogenesis. Proc. Natl. Acad. Sci. USA. 1998;95:9602–9607
  56. Weiner JA, Chun J. Schwann cell survival mediated by the signaling phospholipid lysophosphatidic acid. Proc. Natl. Acad. Sci. USA. 1999;96:5233–5238
  57. Wilson RJ, Cumming KJ. Pituitary adenylate cyclase-activating polypeptide is vital for neonatal survival and the neuronal control of breathing. Respir. Physiol. Neurobiol. 2008;164:168–178
  58. Zhou CJ, Shioda S, Yada T, Inagaki N, Pleasure SJ, Kikuyama S. PACAP and its receptors exert pleiotropic effects in the nervous system by activating multiple signaling pathways. Curr. Protein Pept. Sci. 2002;3:423–439

PII: S0143-4179(09)00112-7

doi: 10.1016/j.npep.2009.10.003

Neuropeptides
Volume 44, Issue 1 , Pages 45-51 , February 2010

Article Tools

* Image Usage & Resolution